ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (NASDAQ:GLYC) today announced that pre-clinical research demonstrating the potential of two of its drug candidates, GMI-1271 and GMI-1359, against multiple myeloma will be shared via an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2017 in Washington, DC. The company and its collaborators at Washington University in St. Louis will highlight data on GMI-1271, an antagonist of E-selectin, and GMI-1359, a dual antagonist of E-selectin and CXCR4, showing anti-cancer activity in preclinical models of multiple myeloma.
The research demonstrated that:
- In cell culture, GMI-1271 and, to a greater extent GMI-1359, reduced multiple myeloma cell adhesion to stromal cells and inhibited chemotaxis of multiple myeloma cells toward conditioned media.
- The presence of GMI-1271 or GMI-1359 reduced stroma-induced drug resistance of multiple myeloma cells to carfilzomib and lenalidomide. In a preclinical model of multiple myeloma, combination therapy of GMI-1271 and lenalidomide profoundly delayed tumor growth.
- Combination therapy of carfilzomib with GMI-1271 or GMI-1359 prolonged survival of mice with multiple myeloma over treatment with carfilzomib alone.
“Our results show a strong effect on cancer cells in combination with chemotherapy and importantly, are supportive of our ongoing Phase 1 clinical studies in multiple myeloma of GMI-1271 as well as our study of GMI-1359 in multiple cancers,” said John Magnani, Ph.D., GlycoMimetics Senior Vice President and Chief Scientific Officer. “These results complement data from other preclinical studies and continue to build the rationale for our on-going clinical programs with both compounds.”
Details of the AACR presentation include:
Abstract #5005—Muz, B.B., et al. “Inhibition of E-Selectin or E-selectin together with CXCR4 re-sensitizes multiple myeloma to treatment.” Tuesday, April 4, 3:00-5:00 p.m. ET.
The AACR Annual Meeting 2017 takes place from April 1 to 5, at the Walter E. Washington Convention Center. Meeting abstracts are available at AACR’s website.
GMI-1271 is currently being evaluated in an ongoing Phase 1/2 clinical trial as a potential treatment for acute myeloid leukemia (AML) and in a Phase 1 clinical trial in multiple myeloma. GMI-1359 is now in a Phase 1 clinical trial.
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company focused on cancer and sickle cell disease. GlycoMimetics' most advanced drug candidate, rivipansel, a pan-selectin antagonist, is being developed for the treatment of vaso-occlusive crisis in sickle cell disease and is being evaluated in a Phase 3 clinical trial being conducted by its strategic collaborator, Pfizer. GlycoMimetics' wholly-owned drug candidate, GMI-1271, an E-selectin antagonist, is being evaluated in an ongoing Phase 1/2 clinical trial as a potential treatment for AML and in a Phase 1 clinical trial in multiple myeloma. GlycoMimetics has also recently initiated a clinical trial with a third drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.
This press release contains forward-looking statements regarding GlycoMimetics’ planned activities with respect to the clinical development of its drug candidates, GMI-1271 and GMI-1359. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the availability and timing of data from ongoing clinical trials, the uncertainties inherent in the initiation of future clinical trials, whether interim results from a clinical trial will be predictive of the final results of the trial or results of early clinical trials will be indicative of the results of future trials, expectations for regulatory approvals, availability of funding sufficient for GlycoMimetics’ foreseeable and unforeseeable operating expenses and capital expenditure requirements, other matters that could affect the availability or commercial potential of GlycoMimetics’ drug candidates and other factors discussed in the “Risk Factors” section of GlycoMimetics’ Annual Report on Form 10-K that was filed with the U.S. Securities and Exchange Commission on February 29, 2016, and other filings GlycoMimetics makes with the Securities and Exchange Commission from time to time. In addition, the forward-looking statements included in this press release represent GlycoMimetics’ views as of the date hereof. GlycoMimetics anticipates that subsequent events and developments may cause its views to change. However, while GlycoMimetics may elect to update these forward-looking statements at some point in the future, GlycoMimetics specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing GlycoMimetics’ views as of any date subsequent to the date hereof.